| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1018685168 |
| P356 | DOI | 10.1186/1471-2474-15-409 |
| P932 | PMC publication ID | 4320526 |
| P698 | PubMed publication ID | 25477192 |
| P5875 | ResearchGate publication ID | 269171719 |
| P2093 | author name string | Lily Y Moy | |
| Jie Zhang-Hoover | |||
| Chi-Sung Chiu | |||
| Robbie L McLeod | |||
| Alan Byford | |||
| Anwar Murtaza | |||
| Dana Stoffregen | |||
| Erica Leccese | |||
| Gain Robinson | |||
| John Shin | |||
| Kalyan Chakravarthy | |||
| Mark Zielstorff | |||
| Michael J Caniga | |||
| Milenko Cicmil | |||
| Raquel Sevilla | |||
| Robert Faltus | |||
| Shuli Zhang | |||
| SuChun Hseih | |||
| Weisheng Zhang | |||
| P2860 | cites work | Gene expression profiles in the rat streptococcal cell wall-induced arthritis model identified using microarray analysis | Q24799004 |
| Anti-cytokine therapy in chronic destructive arthritis | Q24805245 | ||
| Cytokines in the pathogenesis of rheumatoid arthritis | Q28303865 | ||
| The pathogenesis of rheumatoid arthritis | Q29614957 | ||
| Neuronal plasticity: increasing the gain in pain | Q29615421 | ||
| Quantitative assessment of tactile allodynia in the rat paw | Q29617366 | ||
| Animal models of rheumatoid arthritis and their relevance to human disease | Q30438082 | ||
| The American College of Rheumatology (ACR) Core Data Set and derivative "patient only" indices to assess rheumatoid arthritis. | Q31016300 | ||
| Promising bone-related therapeutic targets for rheumatoid arthritis | Q33554023 | ||
| Bioluminescence imaging of myeloperoxidase activity in vivo | Q33700977 | ||
| Inflammatory mediator-induced hypothalamic-pituitary-adrenal axis activation is defective in streptococcal cell wall arthritis-susceptible Lewis rats | Q33847787 | ||
| Mouse/human chimeric monoclonal antibody in man: kinetics and immune response | Q33867651 | ||
| Cytokine pathways and joint inflammation in rheumatoid arthritis | Q33939087 | ||
| Mechanisms of pain | Q33946821 | ||
| Bone damage in rheumatoid arthritis: mechanistic insights and approaches to prevention | Q34001621 | ||
| Anti-interleukin 6 receptor antibody treatment in rheumatic disease | Q34071253 | ||
| Back to the future: oral targeted therapy for RA and other autoimmune diseases | Q34213332 | ||
| Rodent preclinical models for developing novel antiarthritic molecules: comparative biology and preferred methods for evaluating efficacy | Q34497135 | ||
| Cytokines, inflammation, and pain | Q34618022 | ||
| Cytokines in rheumatoid arthritis | Q34637317 | ||
| Mechanisms of pain in arthritis | Q34735644 | ||
| Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a longitudinal observational study | Q35557868 | ||
| Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis | Q35821357 | ||
| Pathogenesis of rheumatoid arthritis: targeting cytokines | Q36242908 | ||
| Arthritis in rats after systemic injection of streptococcal cells or cell walls | Q36337303 | ||
| Pro- and anti-inflammatory roles of interleukin-1 in recurrence of bacterial cell wall-induced arthritis in rats | Q36989932 | ||
| Utility of animal models for identification of potential therapeutics for rheumatoid arthritis | Q37022699 | ||
| Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis | Q37253521 | ||
| The molecular basis of pain and its clinical implications in rheumatology | Q37355730 | ||
| Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists | Q37633537 | ||
| Evaluation of therapeutic targets in animal models of arthritis: how does it relate to rheumatoid arthritis? | Q37761101 | ||
| Animal models for arthritis: innovative tools for prevention and treatment | Q37882852 | ||
| Rheumatoid arthritis in 2012: Progress in RA genetics, pathology and therapy | Q38072312 | ||
| Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis | Q38080683 | ||
| Antinociceptive effects of tumor necrosis factor alpha neutralization in a rat model of antigen-induced arthritis: evidence of a neuronal target | Q39316366 | ||
| New and future agents in the treatment of rheumatoid arthritis. | Q39879130 | ||
| TNF alpha is an effective therapeutic target for rheumatoid arthritis | Q40374598 | ||
| Targeting TNF alpha for the therapy of rheumatoid arthritis. | Q40537686 | ||
| Combined effects of bucillamine and etanercept on a rat type II collagen-induced arthritis model. | Q43105142 | ||
| The kinase inhibitor tofacitinib in patients with rheumatoid arthritis: latest findings and clinical potential | Q43239778 | ||
| In vivo imaging of inflammatory phagocytes | Q44394936 | ||
| Gait abnormalities differentially indicate pain or structural joint damage in monoarticular antigen-induced arthritis | Q44637500 | ||
| Joint cytokine quantification in two rodent arthritis models: kinetics of expression, correlation of mRNA and protein levels and response to prednisolone treatment | Q44935612 | ||
| Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain | Q45230370 | ||
| Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients | Q45554972 | ||
| Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-alpha antibodies | Q46338952 | ||
| Collagen-induced arthritis as a model of hyperalgesia: functional and cellular analysis of the analgesic actions of tumor necrosis factor blockade | Q46873551 | ||
| Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. | Q46881598 | ||
| Rheumatoid arthritis | Q56656479 | ||
| Rheumatoid arthritis | Q57349151 | ||
| Sympathetic or reflex footpad swelling due to crystal-induced inflammation in the opposite foot | Q67368166 | ||
| Reactivation of streptococcal cell wall-induced arthritis by homologous and heterologous cell wall polymers | Q69924798 | ||
| Induction of flare-up reactions in rat antigen-induced arthritis | Q72200943 | ||
| Streptococcal cell wall-induced arthritis. Requirements for neutrophils, P-selectin, intercellular adhesion molecule-1, and macrophage-inflammatory protein-2 | Q73900207 | ||
| Streptococcal cell wall-induced arthritis: requirements for IL-4, IL-10, IFN-gamma, and monocyte chemoattractant protein-1 | Q74506235 | ||
| Rheumatoid arthritis | Q74541001 | ||
| Preferences for improved health examined in 1,024 patients with rheumatoid arthritis: pain has highest priority | Q74714748 | ||
| Non-steroidal anti-inflammatory drugs | Q74786604 | ||
| Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis | Q77341367 | ||
| Mechanical sensation and pain thresholds in patients with chronic arthropathies | Q79301063 | ||
| Animal models of rheumatoid arthritis | Q81503762 | ||
| Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis | Q82690906 | ||
| Are new agents needed to treat RA? | Q84616328 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cell wall | Q128700 |
| P304 | page(s) | 409 | |
| P577 | publication date | 2014-12-04 | |
| P1433 | published in | BMC Musculoskeletal Disorders | Q15751716 |
| P1476 | title | Etanercept ameliorates inflammation and pain in a novel mono-arthritic multi-flare model of streptococcal cell wall induced arthritis | |
| P478 | volume | 15 |
Search more.